Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Investment Securities (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Gains from Investment Securities for 7 consecutive years, with $445000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 104.09% to $445000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 million, a 541.73% increase, with the full-year FY2025 number at $7.1 million, down 61.25% from a year prior.
  • Gains from Investment Securities was $445000.0 for Q4 2025 at Iovance Biotherapeutics, down from $466000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $6.3 million in Q3 2024 to a low of -$10.9 million in Q4 2024.
  • A 3-year average of $1.1 million and a median of $752000.0 in 2024 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 464.97% in 2024; the steepest drop was 5948.39% in 2024.
  • Iovance Biotherapeutics' Gains from Investment Securities stood at $186000.0 in 2023, then plummeted by 5948.39% to -$10.9 million in 2024, then skyrocketed by 104.09% to $445000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Gains from Investment Securities are $445000.0 (Q4 2025), $466000.0 (Q3 2025), and $504000.0 (Q2 2025).